Roche Introduces In-Situ Hybridisation (ISH) Test for the Diagnosis of B-cell Lymphoma
Shots:
- Roche has introduced the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, a highly-sensitive in-situ hybridization (ISH) test, across regions requiring a CE mark to identify B-cell malignancy
- The test can diagnose >60 subtypes of B-cell lymphoma and plasma cell neoplasms using small biopsies and formalin-fixed tissue, minimizing the need for fresh samples
- VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail identifies Kappa mRNA and Lambda mRNA in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue by utilizing chromogenic ISH and light microscopy
Ref: Roche | Image: Roche
Related News:- Roche Highlights Data from the P-III (STARGLO) Trial of Columvi to Treat Diffuse Large B-Cell Lymphoma at EHA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
